Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia

Inclusion Criteria: 1. Patients diagnosed to be non-severe aplastic anemia 2. Patients with platelet count \< 30×109/L and have at least one of the followings: ①absolute neutrophil count \< 1.5×109/L, ②platelet count \< 50×109/L, ③ hemoglobin level \< 100g/L 3. Patients have no response or relapsed following at least one treatment course in a period time of \> 6 months of immunosuppression containing CsA or CsA+anti-thymocyte globulin (ATG); 4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2; 5. Patients able to understand and comply with protocol requirements and instructions and have signed and dated informed consent. Exclusion Criteria: 1. Congenital aplastic anemia; 2. Presence of chromosomal aberration; 3. Evidence of a clonal hematologic bone marrow disorder (MDS, AML) on cytogenetics; 4. Presence with PNH clone ≥50%; 5. Patients received HSCT before; 6. Uncontrolled infection or bleeding with standard treatment; 7. Allergic to Hetrombopag or accessories; 8. HIV, HCV or HBV active infection or liver cirrhosis or portal hypertension; 9. Patient with QTcF (Fridericia's QT correction formula) at screening \<450 msec, or\<480 msec with bundle branch block, as determined via the mean of a triplicate ECG and assessed at site, unstable angina pectoris, uncontrolled hypertension(\>180/100mmHg)，pulmonary artery hypertension; 10. Have any concomitant malignancies within 5 years expect for local basal cell carcinoma of the skin; 11. Past history of thromboembolic event, heart attack or stroke (including anti-phospholipid antibody syndrome) and current use of anticoagulants; 12. Pregnant or nursing (lactating) woman; 13. Have attended other clinical trials within 3 months;